Abstract:
The present invention relates to a vitamin complex composition comprising a green tea extract, a ginkgo leaf extract, a vitamin B group, vitamin C, and ubidecarenone as active ingredients to have an effect of improving a cognitive power and an effect of treating and preventing dementia. The vitamin complex composition comprises a green tea extract containing 300-500 mg of catechin; a ginkgo leaf extract containing 28-36 mg of a flavonol glycoside; 50-100 mg of a vitamin B group; 50-100 mg of vitamin C; and 2.5-10 mg of ubidecarenone.
Caulis ) 추출물 및 목단피( Paeonia Suffruticosa Andrews) 추출물을 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 약제학적 조성물, 의약외품 조성물, 염증의 예방 또는 개선용 건강기능식품 조성물, 화장료 조성물, 상기 약제학적 조성물의 제조방법 및 상기 조성물을 염증성 질환 의심 개체에 투여하는 단계를 포함하는 인간을 제외한 동물의 염증성 질환 치료 방법에 관한 것이다. 본 발명에 따른 조성물은 기존의 낙석등 및 목단피 각각의 추출물과 비교하여 항염증 및 부종 억제 효과가 뛰어난 염증성 질환의 예방, 치료 또는 개선용으로 사용할 수 있고, 천연물 치료제로서 합성 의약품에 비하여 진균감염 및 기타 부작용의 염려가 없는 안전한 치료제를 제공할 수 있으며, 낙석등 및 목단피 추출물의 기존의 항세균, 뼈 보강, 쟁혈, 소염, 대사, 보혈, 원기활성 등의 기능과 작용에 의하여 치료효과의 상승작용을 가져올 수 있다.
Abstract:
PURPOSE: A composition containing mixed extract of Trachelospermi Caulis and Paeonia Suffruticosa Andrews is provided to suppress edema and to prevent or treat inflammatory diseases. CONSTITUTION: A pharmaceutical composition for preventing or treating inflammatory diseases contains Trachelospermi Caulis and Paeonia Suffruticosa Andrews extract as an active ingredient. The extract is isolated using water, alcohol of 1-6 carbon atoms, or mixture solvent thereof. The Trachelospermi Caulis extract contains 0.05-1.5 wt% of arctigenin. The Paeonia Suffruticosa Andrews extract contains 1.8-5.3 wt% of paeoniflorin. A quasi-drug composition for preventing or treating inflammation contains the mixed extract as an active ingredient.
Abstract:
PURPOSE: A method for manufacturing a novel alendronate emulsion dry is provided to produce W/O/W type emulsion by simple process. CONSTITUTION: A method for manufacturing a novel alendronate emulsion dry comprises: a step of adding a solution containing 0.05-5 weight parts of alendronate and 0.05-5 weight parts of chitosan dissolved in 5-100 weight parts of water in a butanol solution in a volume ratio of 2:1-3:1 to prepare W/O type emulsion; a step of adding W/O type emulsion to a solution containing 0.5-2%(w/v) of polyvinyl alcohol solution and 0.7-1%(w/v) sodium chloride solution in a volume ratio of 2:1-10:3 to prepare W/O/W type emulsion; a step of compressing or concentrating the emulsion to remove butanol; a step of adding a solution containing 0.5-20%(w/v) of saccharide selected from a group consisting of mannitol, lactose and glucose in a volume ratio of 2:1-5:1; and a step of drying. A pharmaceutical composition for preventing and treating bone diseases contains alendronate emulsion dry as an active ingredient.